Sematic GLP-1

Structure and Receptor Pharmacology

Sematic GLP-1 is a synthetic incretin peptide analog with a 31-amino acid sequence, designed as a selective monoagonist of the GLP-1R receptor. The structure is based on the native GLP-1(7-37) peptide sequence with key modifications: amino acid substitutions at positions 8 (Ala to Aib) and 34 (Lys to Arg), plus C18 fatty acid acylation at position Lys26 via a glutamic acid linker. The Aib substitution at position 8 stereoelectronically stabilizes the helical conformation of the N-terminus while eliminating the DPP-4 proteolytic cleavage site. The C18 acyl chain provides non-covalent albumin binding, which in in vitro conditions translates to an extended half-life in serum protein-containing solutions.

The molecular weight of the peptide (~4113 Da) and isoelectric point in the range of 4.5 to 5.0 determine its solubility properties. In radioligand binding studies (in vitro), Sematic demonstrates nanomolar affinity for the human GLP-1R receptor with no significant activation of GIPR or GCGR, classifying it as a monoagonist with high receptor selectivity.

Mechanism of Action at the GLP-1R Receptor

The GLP-1R receptor belongs to the class B1 G protein-coupled receptor (GPCR) family. It is a seven-transmembrane domain receptor whose N-terminal extracellular domain (ECD) is responsible for initial ligand recognition, while the transmembrane domains form a binding pocket for the peptide helix. Upon agonist binding, conformational changes in the receptor enable coupling with the Gs protein.

The signaling cascade proceeds as follows: activated Gs protein stimulates adenylyl cyclase (AC), leading to increased intracellular cyclic AMP (cAMP) levels. Elevated cAMP activates protein kinase A (PKA) and Epac2 (Exchange protein directly activated by cAMP). PKA phosphorylates a range of intracellular substrates, including the CREB transcription factor (cAMP Response Element Binding protein), which modulates target gene expression.

In parallel with the Gs/cAMP pathway, agonist binding induces recruitment of beta-arrestin 1 and 2, leading to internalization of the receptor-ligand complex into endosomes. In vitro studies on cell lines overexpressing GLP-1R (HEK293, CHO) have demonstrated that individual GLP-1 analogs can exhibit differential activation profiles of Gs vs. beta-arrestin pathways, a phenomenon termed "biased agonism." The ratio of activation between these two pathways has significant implications for the pharmacological profile of the compound in preclinical studies.

Research Overview

Biology of GLP-1R receptor and the incretin pathway

Drucker DJ in a seminal 2006 review ^[1] presented a comprehensive characterization of incretin hormone biology, with particular focus on GLP-1R receptor pharmacology. The paper describes the structure of the class B1 GPCR receptor, the mechanism of Gs protein coupling, and the cAMP/PKA/CREB signaling cascade. The author detailed the tissue distribution of GLP-1R and the role of DPP-4 enzyme in proteolytic degradation of native GLP-1 peptide.

Structure and function of the GLP-1R receptor

Mayo KE et al. (2003) ^[2] published a detailed analysis of the molecular structure of the GLP-1R receptor, including the organization of transmembrane domains and ligand binding mechanism. Through site-directed mutagenesis studies, key amino acid residues of the ECD domain responsible for recognition of the peptide agonist helix were identified.

Biased agonism of GLP-1R analogs

Wootten D et al. (2013) ^[3] investigated the phenomenon of biased agonism in the context of the GLP-1R receptor. Using a panel of reporter assays in CHO and HEK293 cell lines, the authors demonstrated that individual GLP-1 peptide analogs activate the Gs/cAMP and beta-arrestin pathways in different proportions. Results indicated that the biased signaling profile correlates with receptor internalization kinetics and cell surface recycling.

Beta-arrestin recruitment and GLP-1R internalization

Jorgensen R et al. (2005) ^[4] conducted a series of BRET (Bioluminescence Resonance Energy Transfer) experiments on HEK293 cells overexpressing GLP-1R, demonstrating the kinetics of beta-arrestin 1 and 2 recruitment following agonist stimulation. The authors described the relationship between C-terminal receptor phosphorylation by GRK kinases and internalization efficiency in clathrin-coated pits.

References

1. Drucker DJ. "The biology of incretin hormones." Cell Metabolism. 2006;3(3):153-165.
2. Mayo KE, et al. "International Union of Pharmacology. XXXV. The GCGR Receptor Family." Pharmacological Reviews. 2003;55(1):167-194.
3. Wootten D, et al. "Differential activation and modulation of the GCGR-like peptide-1 receptor by small molecule ligands." Molecular Pharmacology. 2013;83(4):822-834.
4. Jorgensen R, et al. "Characterization of GCGR-like peptide-1 receptor beta-arrestin 2 interaction." Journal of Biological Chemistry. 2005;280(7):6001-6008.

Comparison with Multi-Receptor Agonists

Receptor profile comparison of the monoagonist Sematic with the dual agonist Tirzepic GLP-1 + GIP and the triple agonist Retatric Triple G:

The monoagonistic selectivity of Sematic for GLP-1R serves as a reference point in comparative incretin signaling studies. In experiments on isolated cell lines overexpressing individual receptors, multi-receptor analogs activate additional Gs/cAMP pathways in tissues where GLP-1R expression is low but GIPR or GCGR are dominant.

Stability and Storage

Sematic GLP-1 is supplied as a lyophilized powder with purity above 98% (RP-HPLC). In dry form, store the peptide at -20°C to -80°C for stability of at least 24 months. After reconstitution in sterile water, store at 2-8°C and use within 30 days. Avoid repeated freeze-thaw cycles. The C18 fatty acid acylation enhances peptide stability in solution compared to the native GLP-1 sequence, reducing susceptibility to hydrolytic degradation.

Related Research Materials

Learn more about GLP-1R receptor biology, incretin peptide pharmacokinetics, and the role of DPP-4 enzyme in our knowledge base article GLP-1 and GIP: Incretin Signaling Mechanisms.

Przeznaczenie

Produkt jest surowcem chemicznym przeznaczonym wyłącznie do zastosowań badawczych, naukowych i analitycznych in vitro. Nie jest przeznaczony do użytku ludzkiego ani weterynaryjnego, w tym w celach diagnostycznych, terapeutycznych, profilaktycznych lub żywieniowych.

Obchodzenie się z substancją

• Pracuj w warunkach laboratoryjnych zgodnych z zasadami dobrej praktyki laboratoryjnej (GLP).
• Stosuj odpowiednie środki ochrony indywidualnej: rękawice nitrylowe, okulary ochronne, fartuch laboratoryjny.
• Unikaj wdychania pyłu oraz kontaktu ze skórą i błonami śluzowymi.
• Pracuj w dobrze wentylowanym pomieszczeniu.

Klasyfikacja regulacyjna

Produkt nie jest sklasyfikowany jako substancja niebezpieczna zgodnie z rozporządzeniem CLP (WE) nr 1272/2008. Oferowany jest jako odczynnik chemiczny w ramach obowiązujących w Unii Europejskiej przepisów dotyczących substancji chemicznych (REACH, CLP). Nie stanowi produktu leczniczego, suplementu diety, wyrobu medycznego ani kosmetyku w rozumieniu obowiązujących przepisów prawa.

Utylizacja

Substancję niewykorzystaną należy utylizować zgodnie z lokalnymi przepisami dotyczącymi odpadów chemicznych. W warunkach laboratoryjnych: neutralizować i utylizować wraz z odpadami laboratoryjnymi. Nie wylewać do kanalizacji.

Informacje regulacyjne

Produkt oferowany jest zgodnie z obowiązującymi przepisami Unii Europejskiej dotyczącymi substancji chemicznych (REACH, CLP) oraz prawem polskim w zakresie obrotu odczynnikami chemicznymi i materiałami badawczymi. Pełne warunki sprzedaży oraz klasyfikacja produktu zawarte są w Regulaminie Sklepu.

Dokonując zakupu, Klient potwierdza zapoznanie się z powyższymi informacjami oraz akceptuje postanowienia Regulaminu.

Kontakt w sprawach bezpieczeństwa

W przypadku pytań dotyczących obchodzenia się z produktem lub informacji regulacyjnych: kontakt@peptydy-sklep.com.